Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15243104 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1HCAR2ATM | |
| SCHEMBL4584048 | 0.89 | HCAR2 (0.38) | ALDH1A1TSHRTDP1HCAR2ATM | |
| SCHEMBL9561364 | 0.89 | HCAR2 (0.38) | ALDH1A1TSHRTDP1HCAR2ATM | |
| SCHEMBL4584052 | 0.89 | HCAR2 (0.38) | ALDH1A1TSHRTDP1HCAR2ATM | |
| SCHEMBL2504596 | 0.82 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3870873 | 0.81 | — | — | |
| SCHEMBL9561368 | 0.81 | HCAR2 (0.52) | ALDH1A1TSHRTDP1HCAR2ATM | |
| SCHEMBL1554307 | 0.81 | CNR1 (0.30) | — | |
| SCHEMBL28722546 | 0.81 | KDM4E (0.30) | — | |
| SCHEMBL9561373 | 0.81 | HCAR2 (0.52) | ALDH1A1TSHRTDP1HCAR2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2016179558-A1 | K-RAS MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| WO-2015196144-A2 | ANDROGEN RECEPTOR ANTAGONISTS | ENGLAND PAMELA M (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014144737-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| WO-2013155223-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-7982036-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885TSHR 4633/4885TDP1 2867/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885TSHR 2837/4885TDP1 2415/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885TSHR 4633/4885TDP1 2867/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885TSHR 2837/4885TDP1 2415/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885TSHR 2837/4885TDP1 2415/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885TSHR 2837/4885TDP1 2415/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885TSHR 4633/4885TDP1 2867/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885TSHR 2837/4885TDP1 2415/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | ALDH1A1 3719/4885TSHR 4378/4885TDP1 2059/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885TSHR 4633/4885TDP1 2867/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885TSHR 4633/4885TDP1 2867/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | ALDH1A1 2862/4885TSHR 3877/4885TDP1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.